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Background: Omalizumab is a recombinant humanized monoclonal anti-IgE antibody approved
in adults and adolescents with moderate-to-severe persistent allergic asthma inadequately
controlled with inhaled corticosteroids (ICS). EXCELS is an ongoing prospective observational
cohort study of approximately 5000 omalizumab-treated and >2800 non-omalizumab-treated
patients aged 12 years.
Objective: We evaluated concomitant medication use changes (total ICS dose [including mono-
therapy and combination therapy, fluticasone equivalent], short-acting beta-agonists [SABA],
and leukotriene modifier [LTM]) over 2 years among subsets of patients enrolled in EXCELS.
Methods: Patient subsets included “new starts” (omalizumab initiated at baseline [n Z 549],
“established users” (omalizumab initiated >7 days before baseline [n Z 4421]), and “non-
omalizumab” patients (not treated with omalizumab [n Z 2867]).
Results: At baseline, mean  SD total daily ICS doses were 680  414 mg/d in new starts,
642 431 mg/d in established users, and 548 382 mg/d in non-omalizumab patients. Frombaseline
through year 2, total ICS dose decreased in 65% of new starts (mean SD change,393 504 mg/d),
57%ofestablishedusers (287 492mg/d), and54%ofnon-omalizumabpatients (232 431mg/d).
At baseline, SABA use for new starts, established users, and non-omalizumab patients was 1.9, 1.3,
and 1.4 puffs/d, respectively. At year 2, SABA use decreased in 65% of new starts, 55% of established
users, and 54% of non-omalizumab patients. At year 2, LTM dose decreased in 52% of new starts, 44%
of established users, and 40% of non-omalizumab patients.MS #453A, South San Francisco, CA, USA.
.com (H. Chen).
2 Elsevier Ltd. All rights reserved.
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Concomitant asthma medication use in moderate-to-severe asthma 61Conclusion: Omalizumab therapy initiation was associated with decreased doses of ICS, SABA, and
LTMover2 yearsof follow-up for themajorityofpatients ina“real-world”cohort studyofmoderate-
to-severe allergic asthma patients.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
National guidelines recommend that asthma medications
be titrated to the lowest doses needed to achieve and
maintain asthma control.1 Use of the lowest effective dose
is intended to promote patient safety and reduce the
occurrence of adverse events. Oral corticosteroids (OCS),
for example, are associated with recognized adverse
events, including cataracts and bone fractures.2 Inhaled
corticosteroids (ICS) are considered safer than oral corti-
costeroids; however, concerns with prolonged use of high-
doses of ICS remain3 and the risk of adverse events
increases with ICS dose.1 Due to risks of asthma-related
hospitalization and death, the US Food and Drug Adminis-
tration (FDA) has recommended that long-term beta-
agonists (LABAs) be discontinued once asthma control has
been achieved.4
Despite treatment with high-dose ICS plus LABA combi-
nation therapy, many patients with asthma continue to
have inadequately controlled symptoms.5,6 Omalizumab,
a recombinant humanized monoclonal antibody that binds
to immunoglobulin E (IgE), is approved by the FDA for the
treatment of adolescents and adults (12 years) with
moderate-to-severe persistent allergic asthma that is
inadequately controlled with inhaled corticosteroids.7 In
addition to demonstrating the efficacy of omalizumab for
improving asthma control and reducing exacerbations,
several randomized clinical trials (RCTs) have shown that
omalizumab has an ICS-sparing effect.8e10 In a pooled
analysis of RCTs, omalizumab has also demonstrated an
ability to reduce the need for oral corticosteroid bursts.11
The efficacy of new therapies as demonstrated in RCTs
may not necessarily translate to effectiveness in actual
clinical practice. Subjects in clinical trials are carefully
selected, closely monitored, and often managed within the
context of a strict study protocol. Moreover, most RCTs are
not designed to evaluate longer-term outcomes. Large
prospective, observational studies have the advantage of
yielding more generalizable results that more closely
reflect treatment outcomes as observed in “real-world”
settings. In this study, we examined differences in
concomitant medication use following initiation of omali-
zumab in the Epidemiologic Study of Xolair (omalizumab):
Evaluating Clinical Effectiveness and Long-term Safety in
Patients with Moderate-to-Severe Asthma (EXCELS) study.12Methods
EXCELS study design
EXCELS is an ongoing, multicenter, prospective, observa-
tional cohort study of the long-term clinical safety and
effectiveness of omalizumab. The study has approximately5000 omalizumaband 2500 non-omalizumab-treatedpatients
with moderate-to-severe asthma who were recruited from
a variety of practice settings across the United States.12 The
study design and baseline patient characteristics have been
published previously.12 Because EXCELS is an observational
study, patients are not assigned to any protocol-mandated
treatment.12 The EXCELS protocol was approved by a local
or central institutional review board at each study site and
informed written consent was obtained from study partici-
pants prior to enrolment.Participants
Eligible patients were older than 12 years with a physician
diagnosis of moderate-to-severe persistent asthma and
a positive response to allergy skin testing or in vitro reac-
tivity to a perennial aeroallergen.12 Asthma severity was
assessed by managing physicians and classified as moderate
or severe.12 Key exclusion criteria were a known contrain-
dication to omalizumab therapy, diagnosis of cystic fibrosis,
acute asthma exacerbation within the 2 weeks prior to
screening, or acute flare-up of significant disease or
hospitalization within 2 months prior to screening.12 More
detailed inclusion and exclusion criteria are available
elsewhere.12Medication use
Medication management in EXCELS is determined entirely
by the physician and there is no requirement for attempting
medication tapering.12 All medications (including omalizu-
mab) are initiated, adjusted, and discontinued at the
physician’s discretion.12 Medication type and dose infor-
mation is collected by a study coordinator during patient
interviews and verified by visual inspection of medication
containers provided by patients.Analytic cohort
This interim analysis of concomitant medication use was
conducted using data from the first 2 years of follow-up in
EXCELS,12 and included patients with medication and dose
information at baseline and at least 1 follow-up (month 12
or month 24) study visit. The study population is comprised
of three pre-defined cohorts based on previous use of
omalizumab: New starts had an omalizumab start date
ranging from 7 days prior to the baseline visit date up to
30 days after the baseline visit. Established users had an
omalizumab start date >7 days prior to the baseline visit
date. Non-omalizumab patients had never been treated
with omalizumab at the time of enrolment.12
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Primary analytic outcomes were percent change in dose of
concomitant asthma medications and proportion of
patients with any change in dose from baseline to month 12
and baseline to month 24. Both outcome measures were
evaluated for ICS and short-acting beta-agonists (SABA);
percent change in leukotriene modifier (LTM) dose could
not be reported, as there is no standard for dose equiva-
lence across agents.
ICS was measured as total dose (monotherapy and
combination therapy) and as monotherapy. The doses of all
ICS medications (used as monotherapy or combination
therapy) were converted to fluticasone equivalent prior to
analysis. SABA was measured as number of puffs per day of
regular use, excluding nebulizedmedications anddoses taken
“as needed.” Rescue SABA use was not included due to
inadequate data to allow accurate calculation of numerical
changes. LTM medications included leukotriene receptor
antagonists (montelukast and zafirlukast) and a 5-
lipoxygenase inhibitor (zileuton). Because dose-equivalence
conversion is not possible for LTM, patients who switched
from one LTM to another were excluded from the analysis for
the period when the switch occurred. Oral corticosteroid use
was not systematically collected at follow-up in this study and
was, therefore, not included in this analysis.Statistical analysis
Changes in medication dose were assessed within each
patient subgroup. Statistical tests for between-group
comparisons were not performed due to the observational,
non-randomized nature of EXCELS. For this analysis, oma-
lizumab new starts patients were of primary interest, as this
group was anticipated to best reflect changes in concomi-
tant medication use following initiation of omalizumab
therapy; established users and non-omalizumab patients
served as reference groups.13 Sensitivity analyses examining
patients who switched groups, i.e., non-omalizumab users
who became omalizumab users, or omalizumab users who
discontinued use, showed no substantial differences from
the overall findings reported. In addition, sensitivity anal-
yses adjusting for various baseline imbalances, including
baseline medication use, showed no substantial differences
from the overall findings reported.
Demographic and clinical characteristics at baseline were
summarized by group (new starts, established users, non-
omalizumab) and bymedication subset (ICS, SABA, LTM) using
descriptive statistics. Classification of medication increase or
decrease was based on subtraction of baseline dose from
month 12 andmonth 24 follow-up dose, and were reported as
percent change in dose from baseline and the proportion of
patients with an increase or decrease in dose over time. In
addition to the primary analysis, which evaluated any change
in dose for patients, a wide range of sensitivity analyses were
conductedapplyingdifferent thresholds for defining“change”
in dose. The results from these analyses were not appreciably
different from those reported in the primary analysis.
Given differences in asthma severity at baseline
between groups, additional analyses were conducted
stratifying by asthma severity. Findings stratified by asthmaseverity were not appreciably different from the cohort as
a whole, and thus are presented in the text only.Results
Demographic and baseline clinical characteristics
New starts, established users, and non-omalizumab patients
were similar with respect to most demographic and baseline
characteristics. Overall average age was approximately 45
years, 65%of patientswere femaleand80%werewhite (Table
1); however, the patient groups differed in asthma severity.
Almost half (49.6%) of patients treated with omalizumab
(new starts, 48.3%, established users, 49.6%) were classified
(by their physician) with severe asthma at baseline, but only
23.1% of patients in the non-omalizumab cohort were simi-
larly classified. The distribution of demographic and clinical
characteristics for all patients was similar to those distribu-
tions for the ICS, SABA, and LTM medication subsets. At
baseline, established users had received an average of 8.6
months of omalizumab treatment.Changes in concomitant medication use
Longitudinal changes in medication dose for total ICS, ICS as
monotherapy, and regular SABA use are shown in Table 2.
Mean total daily dose of ICS (mg/d) decreased in all groups
from baseline to month 12 and month 24. The percent
reduction was greatest for new starts (57.7% at month 24)
compared with established users (44.7%) and non-omali-
zumab users (42.4%). The proportion of patients with
change in total ICS dose is shown in Fig. 1. Nearly two-thirds
of omalizumab new starts exhibited a decrease in total
daily ICS dose from baseline to month 24, compared with
57% of established users and 54% of non-omalizumab. When
stratified by asthma severity, the proportion of patients
with an observed decrease in total ICS dose at month 24 was
similar in patients with moderate and severe asthma (new
starts: 64% moderate, 65% severe; established users: 56%
moderate, 58% severe; non-omalizumab: 54% moderate,
53% severe).
While the percent reductions in dose for ICS mono-
therapy were larger than those for ICS total dose for all
groups (both at month 12 and at month 24), the data
exhibited a similar trend overall, with the greatest percent
reduction observed among omalizumab new starts.
For regular SABA use, number of SABA puffs/day
decreased in all groups from baseline tomonth 12 andmonth
24, and the percent reduction was greatest in the new starts
(73.7% at month 24), followed by established users (69.2%),
and non-omalizumab users (64.3%). Fig. 2 shows the
proportion of patients in each subgroupwith changes in daily
SABA use; decreased dose at month 24 was observed in
a greater proportion of new starts (65%) than established
users (55%) or non-omalizumab patients (54%). When strati-
fied by asthma severity, a decrease in regular SABA dose at
month 24 was observed in a somewhat larger proportion of
patients with severe thanmoderate asthma (new starts: 62%
moderate, 69% severe; establishedusers: 49%moderate, 60%
severe; non-omalizumab: 52% moderate, 58% severe).
Table 1 Demographic and baseline clinical characteristics.
All patients (n Z 7837) ICS subseta (n Z 7133) SABA subseta (n Z 826) LTM subseta (n Z 4997)
New starts
(n Z 549)
Established
users
(n Z 4421)
Non-Omalizumab
(n Z 2865)
New starts
(n Z 515)
Established
users
(n Z 4009)
Non-Omalizumab
(n Z 2609)
New
starts
(n Z 77)
Established
users
(n Z 464)
Non-Omalizumab
(n Z 285)
New starts
(n Z 381)
Established
users
(n Z 3029)
Non-Omalizumab
(n Z 1587)
Age, years,
mean (SD)
44.3 (16.0) 44.5 (16.6) 46.2 (17.1) 44.5 (16.1) 44.5 (16.4) 46.2 (17.1) 49.4 (15.3) 46.7 (15.7) 47.5 (17.3) 44.0 (16.3) 44.0 (16.5) 46.2 (17.3)
Sex, n (%)
Men 195 (35.5) 1596 (36.1) 962 (33.6) 191 (37.1) 1441 (35.9) 893 (34.2) 32 (41.6) 176 (37.9) 95 (33.3) 128 (33.6) 1042 (34.4) 496 (31.3)
Women 354 (64.5) 2825 (63.9) 1903 (66.4) 324 (62.9) 2568 (64.1) 1716 (65.8) 45 (58.4) 288 (62.1) 190 (66.7) 253 (66.4) 1987 (65.6) 1091 (68.7)
Race, n (%)
White 430 (78.3) 3493 (79.0) 2348 (82.0) 400 (77.7) 3154 (78.7) 2152 (82.5) 61 (79.2) 371 (80.0) 229 (80.4) 292 (76.6) 2352 (77.7) 1295 (81.7)
Black or
African
American
77 (14.0) 632 (14.3) 366 (12.8) 74 (14.4) 585 (14.6) 330 (12.7) 11 (14.3) 59 (12.7) 40 (14.0) 60 (15.7) 477 (15.8) 218 (13.7)
Asian or
Pacific
Islander
17 (3.1) 102 (2.3) 61 (2.1) 17 (3.3) 94 (2.3) 53 (2.0) 1 (1.3) 10 (2.2) 7 (2.5) 13 (3.4) 71 (2.3) 29 (1.8)
Other 25 (4.6) 193 (4.4) 89 (3.1) 24 (4.7) 175 (4.4) 73 (2.8) 4 (5.2) 24 (5.2) 9 (3.2) 16 (4.2) 128 (4.2) 44 (2.8)
BMI, kg/m2,
mean (SD)
32.2 (18.4) 31.0 (11.8) 31.3 (14.5) 32.0 (15.9) 31.2 (11.7) 31.1 (12.5) 32.1 (6.7) 30.9 (8.5) 33.7 (25.7) 31.4 (11.1) 31.1 (9.9) 31.3 (11.3)
Asthma severity,b n, %
Moderate 282 (51.6) 2222 (50.3) 2200 (76.9) 259 (50.4) 1960 (48.9) 1982 (76.1) 40 (51.9) 221 (47.6) 205 (71.9) 184 (48.4) 1418 (46.8) 1144 (72.2)
Severe 264 (48.4) 2196 (49.7) 660 (23.1) 255 (49.6) 2047 (51.1) 624 (23.9) 37 (48.1) 243 (52.4) 80 (28.1) 196 (51.6) 1610 (53.2) 440 (27.8)
Smoking, n, %
Current 37 (6.7) 205 (4.6) 162 (5.7) 34 (6.6) 184 (4.6) 132 (5.1) 8 (10.4) 21 (4.5) 16 (5.6) 23 (6.0) 140 (4.6) 77 (4.9)
Former 161 (29.3) 1310 (29.6) 833 (29.1) 152 (29.5) 1192 (29.7) 773 (29.6) 29 (37.7) 172 (37.1) 89 (31.2) 115 (30.2) 870 (28.7) 475 (29.9)
Never 351 (63.9) 2904 (65.7) 1870 (65.3) 329 (63.9) 2631 (65.7) 1704 (65.3) 40 (51.9) 271 (58.4) 180 (63.2) 243 (63.8) 2018 (66.6) 1035 (65.2)
SD, standard deviation; BMI, body mass index.
a Among patients with both a baseline and month 12 study visit with valid treatment assignment.
b As defined by investigator.
Table 2 Changes in concomitant medication dose at month 12 and month 24.a
ICS total dose, mg/day ICS monotherapy, mg/day SABA regular use, puffs/day
New starts
(n Z 515)
Established
users
(n Z 4009)
Non-Omalizumab
(n Z 2609)
New starts
(n Z 150)
Established
users
(n Z 1441)
Non-Omalizu b
(n Z 854)
New starts
(n Z 77)
Established
users
(n Z 464)
Non-Omalizumab
(n Z 285)
Dose at baseline,
mean (SD)
680.2 (414.1) 642.4 (430.6) 547.9 (382.4) 256.7 (278.0) 237.9 (263.7) 210.0 (224.6) 1.9 (1.7) 1.3 (1.6) 1.4 (1.7)
Change at month 12,
mean (SD)
297.0 (474.4) 203.0 (457.2) 158.0 (392.7) 158.1 (325.6) 115.8 (297.2) 108.2 (261. 1.5 (1.9) 0.7 (2.0) 0.9 (2.0)
Change at month 24,
mean (SD)
392.8 (503.5) 287.1 (492.2) 232.1 (430.6) 174.0 (309.4) 161.6 (289.1) 126.1 (260. 1.4 (1.9) 0.9 (1.8) 0.9 (1.8)
Percent reduction in dose
Baseline to month
12, %
43.7 31.6 28.8 61.6 48.7 51.5 78.9 53.8 64.3
Baseline to month
24,b %
57.7 44.7 42.4 67.8 67.9 60.1 73.7 69.2 64.3
a Study cohorts for baseline to month 12 analysis and baseline to month 24 analysis based on patients with study visits at those respec e
timepoints with valid treatment assignments; patient counts in table reflect patients with baseline and month 12 study visit with v d
treatment assignment.
b Patient counts for baseline to month 24 as follows (new starts, established users, non-omalizumab): ICS total dose: nZ 467, nZ 37 ,
n Z 2510, respectively; ICS monotherapy: n Z 136, n Z 1390, n Z 829, respectively; SABA regular use: n Z 78, n Z 504, n Z 2 ,
respectively SD, standard deviation.
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Concomitant asthma medication use in moderate-to-severe asthma 65Percent change in LTM dose cannot be reported, as there
is no standard for dose equivalence across agents. Fig. 3
shows the proportion of patients in each subgroup with
changes in LTM use. At month 24, more than 50% of omali-
zumab new starts exhibited reductions in LTM dose,
compared to 44% of established users and 40% of non-oma-
lizumab patients. For the vast majority of patients, a reduc-
tion in LTM dose resulted in complete discontinuation of the
medication: 95.7% formontelukast, 89.6% for zafirlukast, and
91.7% for zileuton. When stratified by asthma severity,
a decrease in LTM dose atmonth 24was observed in a greater
proportion of patientswithmoderate (57%) than severe (48%)
asthmaamongomalizumabnewstarts, butwas similarwithin
the other groups (established users: 43% moderate, 45%
severe; non-omalizumab: moderate 40%, severe 41%).Discussion
The EXCELS study, with its prospective, observational
design and large number of enrolled patients, provides
a unique opportunity to examine concomitant medication
use in “real-world” settings of omalizumab users in clinical
practice. For each of the common asthma medication
classes examined e ICS, SABA, and LTM e the majority of
patients newly treated with omalizumab were able to
decrease medication doses. Although decreases in
concomitant medication use were observed across all three
medication groups, new omalizumab users demonstrated
the greatest percent reduction based on both percent
change in dose of concomitant asthma medications and
proportion of patients with change in dose.
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outcomes, a previous interim analysis of the EXCELS study
demonstrated that initiation of omalizumab was also asso-
ciated with significant improvements in asthma control
from baseline to year 2. On the Asthma Control Test (ACT),
62% of patients newly started on omalizumab achieved the
minimal clinically important difference (3 point increase)
at year 2,13,14 and 59% were well-controlled (20 points on
the ACT) compared with 26% at baseline.15 Thus, the
observed reductions in concomitant medication in this
analysis occurred within the context of an overall clinical
improvement in asthma control in EXCELS.
Notably, results of this analysis parallel similar findings of
ICS dose reduction observed in key clinical trials of omali-
zumab. One pivotal trial10 was designed to evaluate the
ability of omalizumab to decrease ICS use and demonstrateda 57% reduction from baseline in the fluticasone-equivalent
ICS dose after 32 weeks of treatment. Two other trials8,9
included a 4-month steroid-stable phase followed by
a 3-month steroid-reduction phase, in which ICS dose was
reduced according to protocol until discontinuation or
worsening of asthma symptoms. More than 70% of
omalizumab-treated patients were able to reduce ICS dose
by at least 50%, and 40% of patients were able to discontinue
ICS use.8,9 In the current study, mean ICS dose was reduced
by more than 50% among patients treated with omalizumab,
even though the EXCELS study design did not require steroid
reduction and all medication changes were based on the
clinical judgment of the managing physician.12
When treatment with omalizumab is initiated,1 patients
are frequently using multiple other asthma controller
medications. In a recent study of insurance claims frommore
than 6000 patients, Lafeuille et al.16 found that almost 90%
of patients were using agents from three or more asthma
medication classes during the 12months prior to initiation of
omalizumab. A similar proportion were using ICS as part of
their treatment regimen,16 which is consistent with the
findings from EXCELS. Long-term exposure to multiple
medications raises concerns about adverse effects. Unlike
OCS, which are associated with a number of well-known
adverse effects, use of ICS is considered relatively safe.1,2
The adverse effects of ICS increase with dose, however,
and current guidelines recommend using the lowest dose of
ICS that maintains asthma control.1 To the extent that
treatment with omalizumab may facilitate the decrease or
discontinuation of ICS, adverse effects of steroids may be
avoided while maintaining adequate asthma control.
The observational design of EXCELS has both strengths
and limitations. Patients were not assigned to treatment
groups and health care providers made treatment decisions
according to their clinical judgment, thus the results may
have more generalizability to patients as treated in actual
practice.12,13 Nonetheless, sizable reductions in concomi-
tant medication use were observed across all groups likely
as a result of participating in a prospective observational
study with routine follow-up visits. As with most observa-
tional studies, this analysis also has potential for con-
founding (i.e., differences between groups with respect to
asthma severity at baseline) and selection bias (e.g., the
established users group is potentially enriched for patients
who have superior response and tolerability of omalizu-
mab). This analysis should therefore be considered in
conjunction with results from randomized clinical trials.
Other limitations include the fact that dose changes in LTM
could not be evaluated and information about rescue SABA
use was not systematically collected. Finally, it should also
be noted that these results are based on interim data.13Conclusions
In this real-world observational study of omalizumab use in
patients with moderate-to-severe asthma, the greatest
percent reduction in concomitant medication use (ICS, SABA
and LTM) over a 2-year period, based on both percent change
in dose and the proportion of patients with change in dose,
was observed in new omalizumab users when compared with
established users and non-omalizumab users. These findings
Concomitant asthma medication use in moderate-to-severe asthma 67were identifiedwithin the context of improvedasthmacontrol
in theEXCELS study frombaseline toyear 2 and support similar
findings of ICS dose reduction in pivotal trials of omalizumab.
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